Regulators are delaying a trial of an embryonic stem cell treatment for spinal cord injury, drug developer Geron Corp. said Tuesday.
Geron ( GERN - news - people ) said the Food and Drug Administration is reviewing new data from studies of the therapy, called GRNOPC1, on animals. The company plans to start testing its product on humans this summer, but that testing will be delayed during the FDA's review. Geron said it will work with the FDA, and did not estimate how long the review will take.
The product is derived from human embryonic stem cells, and the company says it has tested the drug in 24 separate studies involving rats and mice. The FDA cleared human testing in January, and since then, Geron said it has been studying different doses of the stem cell treatment, and testing it against other neurodegenerative diseases.
The planned trial will involve eight to 10 patients. It plans to recruit patients who recently became paraplegics, meaning they can use their arms but are unable to walk. They will be injected with GRNOPC1 within...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Aggregated News
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
A Mexican standoff with the United States turned into a Mexican smack-down this month with the release of Mexico’s formal rebuttal to US efforts to overturn limits Mexico has ordered on the use of genetically modified (GM) corn and the...
The U.S. government must move “quickly and decisively” to avert substantial national security risks stemming from artificial intelligence (AI) which could, in the worst case, cause an “extinction-level threat to the human species,” says a report commissioned by the U.S...
The Center for Genetics and Society is fiscally sponsored by Tides Center, a 501(c)(3) non-profit organization.
Please visit www.tides.org/state-nonprofit-disclosures for additional information.
